We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Evaluate SC Route of Administration of Ofatumumab in RA Patients

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00686868
First Posted: May 30, 2008
Last Update Posted: June 26, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
GlaxoSmithKline
  Purpose
This study will examine the safety and tolerability, PK and PD of subcutaneously administered GSK1841157 in patients with RA on stable dose Methotrexate. The study comprises a single dose escalation/de-escalation phase to investigate the minimal efficacious dose based on PD markers with an acceptable safety profile.

Condition Intervention Phase
Arthritis, Rheumatoid Other: placebo Drug: ofatumumab Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: Clinical Phase I/IIA Study of Subcutaneously Administration of Ofatumumab in Rheumatoid Arthritis Patients on Stable Dose Methotrexate

Resource links provided by NLM:


Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Safety and tolerability as described by the incidence and severity of adverse events [AEs], clinical laboratory parameters and vital signs. [ Time Frame: throughout the study ]

Secondary Outcome Measures:
  • Requirement for the use of pre-medication, including the timing, type and dose required. [ Time Frame: throughout study ]
  • Pharmacodynamics (B-cell depletion and re-population) as measured by CD-19 peripheral blood B- lymphocyte count via routine fluorescent activated cell sorting (FACS) analysis. [ Time Frame: throughout study ]
  • PK/PD parameters including estimation of time to re-population of CD-19 peripheral blood B-cells to above LLQ (and/or <95% depletion) following single subcutaneous dose of Ofatumumab. [ Time Frame: throughout study ]
  • Immunogenicity as measured by the incidence, titre and type of human anti-human antibody (HAHA) immune response. [ Time Frame: throughout study ]
  • Other pharmacodynamic/biomarkers of disease activity and immune status may include high sensitivity C-reactive protein (hsCRP), Erythrocyte Sedimentation Rate (ESR), B-Lymphocyte Stimulator (BLyS/BAFF), B-Lymphocyte Chemokine (BLC), IL-6, [ Time Frame: throughout study ]
  • Immunoglobulins (IgA, IgG, IgM), Complement (CH50, C3, C4), IgM Rheumatoid Factor (IgM-RF), IgA-RF and IgG-RF, anti-cyclic citrullinated peptide antibody (aCCP), [ Time Frame: throughout study ]
  • serum amyloid A (SAA), CD-3+, CD-4+ and CD-8+ lymphocytes or other biomarkers, as data permit. [ Time Frame: throughout study ]
  • Pharmacodynamics (B-cell depletion and re-population) as measured by CD-19 peripheral blood B- lymphocyte count via routine FACS analysis.Other Secondary Endpoints [ Time Frame: throughout study ]

Enrollment: 35
Actual Study Start Date: June 13, 2008
Study Completion Date: May 2, 2011
Primary Completion Date: March 11, 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 30mg
active
Drug: ofatumumab
fully human anti-CD20 monoclonal antibody
Experimental: 3mg
active
Drug: ofatumumab
fully human anti-CD20 monoclonal antibody
Experimental: 0.3mg
active
Drug: ofatumumab
fully human anti-CD20 monoclonal antibody
Placebo Comparator: placebo
placebo
Other: placebo
placebo
Experimental: 60mg
60mg
Drug: ofatumumab
fully human anti-CD20 monoclonal antibody
Experimental: 100mg
100mg
Drug: ofatumumab
fully human anti-CD20 monoclonal antibody

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria:

  • Male or female aged ≥ 18 years
  • A diagnosis of rheumatoid arthritis according to the American College of Rheumatology (ACR1987 classification) of at least six months prior to screening
  • Subjects must be treated with MTX, 7.5-25 mg/week, for at least 12 weeks prior to Visit 2, with the last 4 weeks prior to Day 2 at a stable dosage
  • Patient must be willing to receive folic acid ≥5mg/wk 4 weeks prior to baseline administered according to locally accepted practice
  • Body mass index (BMI) < 35kg/m2 (inclusive)
  • Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form

Key Exclusion Criteria:

  • Subjects with a history of a rheumatic autoimmune disease other than RA (except secondary Sjögren's syndrome), or with significant systemic involvement secondary to RA (vasculitis, pulmonary fibrosis or Felty's syndrome)
  • Previous exposure to biologic cell depleting anti-rheumatic therapies, including investigational compounds (e.g. anti-CD11a, anti-CD19, anti-CD20, anti-CD22, anti-BLyS/BAFF, anti-CD3, anti-CD4, anti-CD5, anti-CD52)
  • Exposure to etanercept < 4 weeks, infliximab or adalimumab < 8 weeks, or abatacept or anakinra < 12 weeks prior to visit 2
  • Received any of the following treatments within 4 weeks prior to Visit 2:
  • Anti-cancer therapy (e.g. alkylating agents, anti-metabolites, purine analogues, monoclonal antibodies)
  • Glucocorticoid unless given in doses equivalent to ≤ 10 mg of prednisolone /day
  • Intra-articular, i.m. or IV corticosteroids
  • Live/attenuated vaccinations
  • Cyclosporine
  • Azathioprine
  • Penicillamine
  • Sulfasalazine
  • Bucillamine
  • Hydroxychloroquine
  • Chloroquine
  • Exposure to leflunomide within 12 weeks prior to visit 2 unless the subject has completed peroral cholestyramine treatment
  • Exposure to gold therapy ≤ 12 weeks prior to Visit 2
  • Exposure to IV immunogammaglobulins ≤ 24 weeks prior to Visit 2
  • Past or current malignant melanoma
  • Chronic or ongoing active infectious disease requiring systemic treatment such as, but not limited to, renal infection, chest infection with bronchiectasis, tuberculosis and active hepatitis B and C
  • History of significant cerebrovascular disease
  • Positive plasma / white cell JC Virus (JCV) PCR (either compartment)
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00686868


Locations
United States, Alabama
GSK Investigational Site
Anniston, Alabama, United States, 36207
United States, Florida
GSK Investigational Site
Miramar, Florida, United States, 33025
Australia, New South Wales
GSK Investigational Site
Randwick, New South Wales, Australia, 2031
Australia, South Australia
GSK Investigational Site
Adelaide, South Australia, Australia, 5000
Australia, Victoria
GSK Investigational Site
Heidelberg, Victoria, Australia, 3084
GSK Investigational Site
Melbourne, Victoria, Australia, 3004
Belgium
GSK Investigational Site
Brussels, Belgium, 1200
GSK Investigational Site
Leuven, Belgium, 3000
France
GSK Investigational Site
Echirolles, France, 38130
Italy
GSK Investigational Site
Verona, Veneto, Italy, 37126
New Zealand
GSK Investigational Site
Christchurch, New Zealand, 8011
Poland
GSK Investigational Site
Bydgoszcz, Poland, 85168
Russian Federation
GSK Investigational Site
Moscow, Russian Federation, 115522
GSK Investigational Site
Ryazan, Russian Federation, 390026
GSK Investigational Site
Smolensk, Russian Federation, 214018
GSK Investigational Site
Yaroslavl, Russian Federation, 150003
Spain
GSK Investigational Site
Madrid, Spain, 28046
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT00686868     History of Changes
Other Study ID Numbers: OFA110867
First Submitted: May 28, 2008
First Posted: May 30, 2008
Last Update Posted: June 26, 2017
Last Verified: June 2017

Keywords provided by GlaxoSmithKline:
GSK1841157;
rheumatoid arthritis,
B-cell depletion
anti-CD20 monoclonal antibody,

Additional relevant MeSH terms:
Arthritis
Arthritis, Rheumatoid
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Antibodies, Monoclonal
Rituximab
Immunologic Factors
Physiological Effects of Drugs
Antineoplastic Agents
Antirheumatic Agents